Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimenMeghan C. Thompson, Anthony R. Mato, Paul M. Barr et al.|Blood Advances|2022Cited by 57
MAJIC: A Phase III Trial of Acalabrutinib + Venetoclax versus Venetoclax + Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaChristine E. Ryan, Lindsey E. Roeker, Matthew S. Davids et al.|Future Oncology|2022Cited by 35
Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Naïve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)Jennifer R. Brown, William G. Wierda, Matthew S. Davids et al.|Blood|2019Cited by 13